Pharmacovigilance Market - Global Forecast 2026-2032: Increased Collaboration Across Sectors Present New Challenges And Opportunities For Patient Safety And Compliance

(MENAFN- GlobeNewsWire - Nasdaq) Opportunities stem from tech adoption, proactive risk management, and regional regulatory adaptability, supported by hybrid models and collaboration for enhanced pharmacovigilance efficiency.

Dublin, April 08, 2026 (GLOBE NEWSWIRE) -- The "Pharmacovigilance Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets's offering.

The Pharmacovigilance Market expanded from USD 11.84 billion in 2025 to USD 13.71 billion in 2026. It is projected to sustain a compound annual growth rate (CAGR) of 16.34%, ultimately reaching USD 34.17 billion by 2032.

This growth is driven by intensifying global regulatory oversight, rising adoption of advanced technologies, and increasing complexity in therapeutic development, all of which raise the bar for drug safety monitoring and compliance frameworks. The evolving market landscape is compelling organizations to reassess their investment priorities and integrate capabilities that ensure consistent, enterprise-wide vigilance.

The pharmacovigilance market is undergoing significant transformation as regulatory requirements, technological advancements, and increased collaboration across sectors present new challenges and opportunities for patient safety and compliance. Senior decision-makers must now navigate a highly interconnected landscape that demands agile strategies for both regulatory adherence and operational effectiveness.

Key Takeaways for Senior Decision-Makers

• Pharmacovigilance now extends well beyond reactive adverse event reporting, with increasing focus on proactive risk management and integration of real-world evidence.
• Collaboration between clinical, regulatory, and data science teams enhances the reliability and speed of safety surveillance, while supporting rapid pattern recognition for emerging risks.
• Adopting hybrid operating models, blending in-house leadership with selective outsourcing, allows organizations to scale efficiently, leverage specialized expertise, and address fluctuating case workload.
• The adoption of artificial intelligence, automation, and machine learning is expediting data processing, enabling more effective identification and management of relevant safety signals from diverse data streams.
• Distinct regional regulatory requirements and unequal data maturity demand that global organizations maintain adaptable approaches while meeting both centralized and localized compliance standards.
• Continuous workforce upskilling and investment in regulatory intelligence are paramount for staying ahead of evolving industry requirements and ensuring consistent operational oversight.

Scope & Segmentation of the Pharmacovigilance Market

• Type: Cohort event monitoring, EHR mining, intensified ADR reporting, spontaneous reporting, targeted spontaneous reporting. Each method addresses distinct surveillance priorities, allowing for adaptable pharmacovigilance strategies suited to varying risk profiles.
• Product Life Cycle: Pre-clinical, Phase I, Phase II, Phase III, Phase IV. Pharmacovigilance interventions are customized at every product lifecycle stage, ensuring comprehensive monitoring from early development through post-market surveillance.
• Delivery Mode: In-house, outsourced. Organizations balance cost, expertise, and control by selecting flexible delivery models aligned to case volume and complexity.
• Process Flow: Case data management, risk management systems, signal detection. Each function provides an integrated approach to adverse event tracking, risk evaluation, and medical review, supporting timely regulatory submissions and informed decision-making.
• Therapeutic Area: Cardiovascular, infectious diseases, neurology, oncology, respiratory. This segmentation enables teams to prioritize interventions in high-need areas and address regulatory nuances unique to each therapy.
• End User: Biotechnology companies, medical device manufacturers, pharmaceuticals. Stakeholders in these sectors rely on tailored pharmacovigilance solutions to address varying compliance and operational needs.
• Region: Americas, Europe, Middle East & Africa, Asia-Pacific. Regional segmentation supports locally compliant approaches while maintaining global standards, factoring in jurisdictional variation in regulation and data privacy.
• Technologies: Artificial intelligence, machine learning, automation tools, data pipelines, real-world data integration. These technologies transform traditional reporting and risk detection workflows, enabling greater efficiency and predictive insight.

Why This Report Matters

• Supports strategic investment decisions by offering actionable insights into shifting pharmacovigilance processes, technology deployment, and regulatory changes.
• Delivers executives clear direction for governance, sourcing, and operational compliance across multiple regions and therapeutic areas.
• Enables organizations to build resilience and future readiness using tailored recommendations aligned to their product portfolios and local market demands.

Conclusion

Pharmacovigilance leaders face a landscape marked by regulatory sophistication, technology-driven change, and global operational challenge. This report provides decision-makers with the clarity and context essential to promote robust compliance, safeguard patient outcomes, and maintain operational strength.

Key Attributes:

Report Attribute	Details
No. of Pages	192
Forecast Period	2026 - 2032
Estimated Market Value (USD) in 2026	$13.71 Billion
Forecasted Market Value (USD) by 2032	$34.17 Billion
Compound Annual Growth Rate	16.3%
Regions Covered	Global

Executive Summary

• CXO Perspective
• Market Size & Growth Trends
• Market Share Analysis, 2025
• FPNV Positioning Matrix, 2025
• New Revenue Opportunities
• Next-Generation Business Models
• Industry Roadmap

Market Overview

• Industry Ecosystem & Value Chain Analysis
• Supply-Side Analysis
• Demand-Side Analysis
• Stakeholder Analysis
• Porter's Five Forces Analysis
• PESTLE Analysis
• Market Outlook
• Near-Term Market Outlook (0-2 Years)
• Medium-Term Market Outlook (3-5 Years)
• Long-Term Market Outlook (5-10 Years)
• Go-to-Market Strategy

Market Insights

• Consumer Insights & End-User Perspective
• Consumer Experience Benchmarking
• Opportunity Mapping
• Distribution Channel Analysis
• Pricing Trend Analysis
• Regulatory Compliance & Standards Framework
• ESG & Sustainability Analysis
• Disruption & Risk Scenarios
• Return on Investment & Cost-Benefit Analysis

Companies Featured

• Accenture, PLC
• Bristol-Myers Squibb Company
• Capgemini SE
• ClinChoice
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• HCL Technologies Limited
• ICON PLC
• Infosys Limited
• International Business Machines Corporation
• IQVIA Inc.
• ITclinical
• Laboratory Corporation of America Holdings
• Linical Co., Ltd.
• Novartis AG
• Oracle Corporation
• Parexel International
• Pfizer Inc.
• Quanticate International limited
• Sanofi S.A.
• Syneos Health
• TAKE Solutions Limited
• TATA Consultancy Services Limited
• Wipro Limited

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Pharmacovigilance Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN08042026004107003653ID1110956452